TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
Sports
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | United StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My MoneyAutoZone
UPSC | Exam ScheduleExam Mentor
Don't Miss
Advertisement

Drug controller permits phase 2, 3 trials on Covishield vaccine candidate; Chandigarh PGI among 17 trial sites

The vaccine recently showed promising results in phase 1 trials in the UK

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

Aditi Tandon

Advertisement

Tribune News Service

Advertisement

New Delhi, August 4

In less than a month after the Serum Institute applies to the Drug Controller General of India for permission to conduct phase 2 and 3 clinical trials of the Oxford University-Astra Zeneca vaccine candidate Covishield, the apex regulator has granted the permission.

The permission was given on Sunday after Adar Poonawala led Serum Institute satisfies certain requirements the drug Controller sought earlier this week in the design of the proposal.

Advertisement

PGI in Chandigarh is among the trial sites listed in the study, which will involve administration of the vaccine to 1,600 people healthy adults across trials at 17 sites.

Other sites include AIIMS in Delhi, ABJ Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, AIIMS in Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

The design says every healthy human volunteer for the trial will be given two doses — the second one at a duration of four weeks.

If the first is administered today the second will be administered at day 29.

Then immunogenicity data will be assessed. The vaccine recently showed promising results  in phase 1 trials in the UK and did not present any serious adverse side effects.

It’s safety was determined in phase 1 trials. Phase 2 and 3 trials are done on a larger human population to see if the vaccine produces the required protections against COVID-19 in humans.

Advertisement
Show comments
Advertisement